Pharma PR agency India
Backed by App\Support\NamedExperts::get(). --}}
Regulatory-friendly public relations for pharmaceutical, OTC, medical device and biotech brands. DCGI approval PR, launch PR, KOL coordination, medical-writer alignment, adverse-event readiness, and awards — every asset written to UCPMP 2024, ASCI Chapter III, DPDP 2023 and Drugs and Magic Remedies Act discipline. Custom-scoped retainer starting from ₹20,000 per month. One written scope, one Co-Founder accountable, one dedicated pharma pod.
What pharma PR is, and why it sits on a higher retainer band than clinical-side PR.
Pharma PR is the retainered practice that runs public communications for a pharmaceutical, OTC, medical device or biotech brand under a rulebook that clinical-side PR does not have to navigate — the Uniform Code for Pharmaceutical Marketing Practices 2024, sitting on top of ASCI Chapter III, DPDP 2023 and the Drugs and Magic Remedies Act. Every asset — the press release, the byline, the KOL quote, the launch pack, the adverse-event holding statement — needs a medical-writer review layer before it goes public, and a pharmacovigilance-aware readiness layer standing by in case an adverse-event story lands. Because the compliance filter is heavier, the retainer is custom-scoped, starting from ₹20,000 per month. A live adverse-event story triggers a separate Crisis Engagement of ₹3,00,000 to ₹7,00,000 depending on severity. All prices are inclusive of GST at 18 per cent and fixed for the length of the contract.
Six lanes that keep a pharma brand in category conversation and out of regulatory attention.
A pharma PR retainer covers six lanes running in parallel, each governed by a distinct compliance filter. Owning any one lane in isolation leaves the brand exposed. All six sit inside the retainer.
Lane 1 · Regulatory-friendly product PR
Product story built from the DCGI-approved pack insert, not from the sales deck. Indication language cited to the letter. Efficacy claims replaced with mechanism-of-action framing and cited clinical-trial summaries.
Lane 2 · DCGI approval PR
Press communications timed around Central Drugs Standard Control Organisation clearances. Approval letter, indication summary, therapeutic positioning, published pack inserts and clinical-writer coordination.
Lane 3 · Launch PR
12 to 16 week lead — DCGI review, KOL brief, medical-writer alignment, press pack drafting, embargo coordination, trade press briefings, launch-day activation and four-week post-launch coverage layer.
Lane 4 · KOL coordination
UCPMP-disclosed KOL engagement across cardiology, oncology, endocrinology, gastroenterology, pulmonology, dermatology, nephrology, neurology and gynaecology. Honoraria schedule, conflict declaration, published-piece review.
Lane 5 · Medical-writer coordination
Every asset that leaves the retainer runs through a medical-writer review layer — clinical accuracy, indication compliance, citation discipline. The layer that turns a marketing draft into a UCPMP-safe PR asset.
Lane 6 · Adverse-event PR readiness
Standing pharmacovigilance-aware playbook, spokesperson prep, quote library referencing DCGI-approved pack inserts. Escalates to a paid Crisis Engagement when a live adverse-event story activates.
Pricing
Retainers from ₹20,000/month · Custom-scoped per engagement.
The four rulebooks that decide what a pharma brand can say in Indian public press.
UCPMP 2024
Uniform Code for Pharmaceutical Marketing Practices — restricts promotional claims, gifts, hospitality and testimonials, requires KOL disclosure. Every asset runs through the UCPMP filter before it leaves the pod.
ASCI Chapter III
Health-claim restrictions on public advertising. Applies to OTC pharma and consumer-facing pharma copy. Superlative and comparative language routed out at draft stage.
DMR Act (Drugs and Magic Remedies)
Restricts advertising of drugs claiming to treat specified diseases. Applies to OTC and Ayurveda-adjacent formulations. Every consumer-side pharma PR asset runs a DMR filter.
DPDP 2023
Personal data disclosure requires consent. Trial-participant identifiers, patient case studies and prescriber names cannot appear in public press without a signed DPDP consent form on file.
A 16-week pharma launch runs on a written pre-launch, launch and post-launch rhythm.
The single largest source of pharma launch failure at PR is compressed lead time. 12 to 16 weeks is the standard for a new molecule; 6 to 10 weeks for a line extension. Anything shorter runs as a Launch Sprint at a separate one-time fee.
Weeks 1–4 · DCGI + brief
DCGI approval letter review, indication summary, therapeutic positioning, KOL panel confirmation, medical-writer alignment, press pack draft v1.
Weeks 5–8 · Pack + KOL prep
Press pack v2, KOL briefs, embargo list, trade-press pre-briefings, medical-journal alignment, spokesperson media training, adverse-event playbook refresh.
Weeks 9–12 · Launch activation
Embargo lift day. Coordinated coverage across trade, business, digital-native and mainstream. KOL commentary rounds. Spokesperson interviews. First-week SOV lock.
Weeks 13–16 · Post-launch coverage
Sustained coverage layer, KOL bylines, therapy-area conference angles, follow-up analyst commentary, first prescriber-recall pulse, post-mortem and month-6 plan.
Who a pharma PR retainer fits — and who it does not.
A pharma retainer fits
- Prescription pharma brands with a launch calendar or DCGI approvals pending.
- OTC pharma and consumer-health brands running ASCI-restricted category conversations.
- Medical device brands with CDSCO approval PR or hospital-KOL coordination needs.
- Biotech companies preparing IPO, funding announcements or trial-milestone news.
- Diagnostic-device and imaging-platform companies with clinical-evidence positioning.
- Portfolio pharma houses needing multi-therapy-area coverage rhythm.
A pharma retainer does not fit
- Brands wanting efficacy claims placed in mainstream press — UCPMP will not allow it.
- Brands wanting cure claims placed under DMR-restricted categories.
- Brands wanting KOL testimonials without honorarium disclosure — UCPMP breach.
- Product launches with less than 4 weeks of PR lead — runs as a Launch Sprint or not at all.
- Brands wanting competitor pharma names inside pitches — will not do it, at any price.
Pharma PR retainer · pricing and scope FAQ.
What does a pharma PR agency in India actually do?
A pharma PR agency runs the communication lanes that UCPMP 2024 restricts inside the sales channel — regulatory-friendly product PR, DCGI approval communications, launch PR, KOL coordination, medical-writer alignment, adverse-event communications and industry awards. Every asset is written to UCPMP-clean discipline, DPDP-consented, and cleared for public press before it leaves the retainer.
Why does pharma PR cost more than clinical-side PR?
UCPMP 2024 clean-copy discipline needs a medical-writer review layer on every asset. KOL coordination is a specialised workflow with legal edges. Adverse-event PR readiness requires a standing pharmacovigilance-aware playbook. Pharma retainers are custom-scoped, starting from ₹20,000 per month.
What is UCPMP 2024 and how does it change what a pharma PR agency can say?
The Uniform Code for Pharmaceutical Marketing Practices 2024 restricts promotional claims, gifts, incentives, event hospitality and testimonials, and requires disclosure of KOL relationships. Every pharma PR asset must avoid efficacy language in public, avoid testimonials, disclose KOL honoraria appropriately and cite only DCGI-approved indications.
How much does pharma PR cost per month in India?
Custom-scoped retainer starting from ₹20,000 per month, priced against lane count, launch cadence and portfolio size. All prices are inclusive of GST at 18 per cent and fixed for the length of the contract.
Does the retainer include DCGI approval PR?
Yes — from engagement upwards, DCGI approval PR is included as a standing capability. Assets are drafted from the DCGI approval letter, run through the UCPMP filter, cleared with the medical affairs lead, and released on the approved indication only.
How does ICG coordinate KOLs under UCPMP?
A written KOL engagement protocol per retainer — role definition, honorarium schedule, disclosure norms, published-piece review process, event hospitality caps, conflict-of-interest declaration. ICG maintains a specialty-mapped KOL roster across cardiology, oncology, endocrinology, gastroenterology, pulmonology, dermatology, nephrology, neurology and gynaecology.
What about launch PR — how much lead time is needed?
12 to 16 weeks for a new molecule. 6 to 10 weeks for line extensions and refreshes. Rush launches inside 4 weeks are billed as a Launch Sprint (one-time ₹3,00,000 to ₹8,00,000 depending on complexity).
What happens if a product has an adverse-event story in the press?
The retainer covers standing adverse-event PR readiness. A live adverse-event story triggers a Crisis Engagement (₹3,00,000 to ₹7,00,000 depending on severity) that runs alongside the retainer.
Can medical devices sit on the pharma PR retainer?
Yes. Medical devices sit on the pharma retainer band because CDSCO device approval PR, clinical-evidence positioning and hospital-KOL coordination follow the same rulebook family as pharmaceuticals.
Does ICG serve pharma OTC brands as well as prescription?
Yes. OTC brands run on the same retainer band because ASCI Chapter III and DMR Act restrictions both apply. OTC PR runs a slightly different copy filter — ASCI-first plus DMR-first.
What awards does a pharma PR retainer chase?
Recognised sector properties with named editors and credible juries — pharma trade awards, medical-device recognition, ET Healthworld and BW Businessworld properties, therapy-area society awards. ICG does not pursue paid-entry awards.
How is a pharma PR retainer measured?
Six numbers monthly. Coverage volume by outlet tier. Editorial share of voice inside your therapy area. Prescriber-brand recall (surveyed quarterly). Awards secured or shortlisted. KOL LinkedIn follower velocity. Adverse-event coverage tone tracking.
Deeper into pharma-side comms and adjacent services.
Pick a band. Sign one page. Live inside 3 weeks.
The Discovery call is 45 minutes with a Co-Founder or the Head of Pharma PR, free of charge, no obligation. You leave the call with a tier recommendation, a baseline audit, and a launch calendar mapped against your DCGI pipeline.
